| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Suvorexant | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of excessive sedation |
If coadministering, initiate dose at 5 mg daily. May increase to 10 mg daily if not effective. Monitor for excessive sedation. |
|||
| Darunavir Suvorexant 950 | Red: Avoid combination | Do not coadminister: Potential for increased suvorexant levels | Potential for increased risk of suvorexant adverse effects |
Use alternative agents |
|||
| Elvitegravir Suvorexant 211 | Red: Avoid combination | Do not coadminister: Potential for increased levels of suvorexant | Potential for increased suvorexant adverse effects |
Use alternative agents |
